– Atlas Venture, a leading early-stage venture capital firm in biotech, closed its third Opportunity Fund, raising $400 million in an oversubscribed round.
– Opportunity Fund III enables Atlas to provide longitudinal capital to portfolio companies as they pursue subsequent financings and advance therapeutic programs.
– The fundraise follows Atlas’ $450 million Fund XIV, its latest early-stage vehicle, which closed in December 2024.
– Atlas’ partnership highlighted strong portfolio progress despite challenges in the biotech sector and emphasized the bespoke investment strategy of Opportunity Fund III.
– The two-fund model consists of dedicated early-stage and growth capital, supporting companies from seed/Series A through later-stage financings.
– Early-stage investments are incubated with the help of entrepreneurs-in-residence, forming new biotech companies around promising science sourced globally.
– Opportunity Fund III allows Atlas to continue investing in select later-stage private and public financings, combined with ongoing strategic support.
– Atlas Venture has over 30 years of experience building biotechnology companies.
– The investment team works across both early-stage and opportunity funds to maximize therapeutic development and value recognition.
– General partners for Opportunity Fund III are Kevin Bitterman, Bruce Booth, Michael Gladstone, and Jason Rhodes.
– Jean-Francois Formela and David Grayzel continue as partners, contributing their experience across the firm.
